141 related articles for article (PubMed ID: 9655844)
1. First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate.
Neuwelt EA; Brummett RE; Doolittle ND; Muldoon LL; Kroll RA; Pagel MA; Dojan R; Church V; Remsen LG; Bubalo JS
J Pharmacol Exp Ther; 1998 Jul; 286(1):77-84. PubMed ID: 9655844
[TBL] [Abstract][Full Text] [Related]
2. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors.
Doolittle ND; Muldoon LL; Brummett RE; Tyson RM; Lacy C; Bubalo JS; Kraemer DF; Heinrich MC; Henry JA; Neuwelt EA
Clin Cancer Res; 2001 Mar; 7(3):493-500. PubMed ID: 11297239
[TBL] [Abstract][Full Text] [Related]
3. Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption.
Neuwelt EA; Gilmer-Knight K; Lacy C; Nicholson HS; Kraemer DF; Doolittle ND; Hornig GW; Muldoon LL
Pediatr Blood Cancer; 2006 Aug; 47(2):174-82. PubMed ID: 16086410
[TBL] [Abstract][Full Text] [Related]
4. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity.
Muldoon LL; Pagel MA; Kroll RA; Brummett RE; Doolittle ND; Zuhowski EG; Egorin MJ; Neuwelt EA
Clin Cancer Res; 2000 Jan; 6(1):309-15. PubMed ID: 10656463
[TBL] [Abstract][Full Text] [Related]
5. In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity.
Neuwelt EA; Brummett RE; Remsen LG; Kroll RA; Pagel MA; McCormick CI; Guitjens S; Muldoon LL
Cancer Res; 1996 Feb; 56(4):706-9. PubMed ID: 8630999
[TBL] [Abstract][Full Text] [Related]
6. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels.
Dickey DT; Wu YJ; Muldoon LL; Neuwelt EA
J Pharmacol Exp Ther; 2005 Sep; 314(3):1052-8. PubMed ID: 15951398
[TBL] [Abstract][Full Text] [Related]
7. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma.
Parsons SK; Neault MW; Lehmann LE; Brennan LL; Eickhoff CE; Kretschmar CS; Diller LR
Bone Marrow Transplant; 1998 Oct; 22(7):669-74. PubMed ID: 9818694
[TBL] [Abstract][Full Text] [Related]
8. Ototoxic protection of sodium thiosulfate: daily vs constant infusion.
Stocks RM; Gould HJ; Bush AJ; Dudney BW; Pousson M; Thompson JW
Otolaryngol Head Neck Surg; 2004 Jul; 131(1):115-9. PubMed ID: 15243567
[TBL] [Abstract][Full Text] [Related]
9. Preventing platinum-induced ototoxicity in children-is there a potential role for sodium thiosulfate?
Skinner R
Pediatr Blood Cancer; 2006 Aug; 47(2):120-2. PubMed ID: 16206212
[No Abstract] [Full Text] [Related]
10. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M
Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378
[TBL] [Abstract][Full Text] [Related]
11. Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children.
Macdonald MR; Harrison RV; Wake M; Bliss B; Macdonald RE
J Otolaryngol; 1994 Jun; 23(3):151-9. PubMed ID: 8064951
[TBL] [Abstract][Full Text] [Related]
12. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens.
Dean JB; Hayashi SS; Albert CM; King AA; Karzon R; Hayashi RJ
J Pediatr Hematol Oncol; 2008 Feb; 30(2):130-4. PubMed ID: 18376265
[TBL] [Abstract][Full Text] [Related]
13. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
Jahnke K; Kraemer DF; Knight KR; Fortin D; Bell S; Doolittle ND; Muldoon LL; Neuwelt EA
Cancer; 2008 Feb; 112(3):581-8. PubMed ID: 18072268
[TBL] [Abstract][Full Text] [Related]
14. Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach.
Orgel E; Jain S; Ji L; Pollick L; Si S; Finlay J; Freyer DR
Pediatr Blood Cancer; 2012 Jun; 58(6):953-8. PubMed ID: 21796767
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of carboplatin brainstem infusions on hearing thresholds in monkeys.
May BJ; Guarnieri M; Carson BS; Bachani A; Jallo GI
Arch Otolaryngol Head Neck Surg; 2004 Dec; 130(12):1411-5. PubMed ID: 15611401
[TBL] [Abstract][Full Text] [Related]
17. Time response of carboplatin-induced hearing loss in rat.
Husain K; Scott B; Whitworth C; Rybak LP
Hear Res; 2004 May; 191(1-2):110-8. PubMed ID: 15109710
[TBL] [Abstract][Full Text] [Related]
18. [Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention].
Montaguti M; Brandolini C; Ferri GG; Hatzopoulos S; Prete A; Pession A
Acta Otorhinolaryngol Ital; 2002 Feb; 22(1):14-8. PubMed ID: 12236007
[TBL] [Abstract][Full Text] [Related]
19. [The ototoxicity of the cytostatic drug carboplatin in patients with head-neck tumors].
Bauer FP; Westhofen M; Kehrl W
Laryngorhinootologie; 1992 Aug; 71(8):412-5. PubMed ID: 1388466
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
